PRLD Prelude Therapeutics Incorporated
Healthcare$4.09-4.22%ClosedMarket Cap: $232.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.85
P/S
14.54
EV/EBITDA
-2.90
DCF Value
$3.63
FCF Yield
-18.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.7%
Operating Margin
-503.2%
Net Margin
-465.3%
ROE
-118.2%
ROA
-65.0%
ROIC
-104.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $4.6M | 91.5% | $-14.2M | $-10.4M | $— | — |
| Q4 null | $5.6M | 100.0% | $-17.3M | $-16.5M | $— | — |
| FY null | $12.1M | 85.9% | $-104.6M | $-99.5M | $— | — |
| Q3 null | $6.5M | 100.0% | $-20.4M | $-19.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-32.2M | $-31.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.6M | $-32.1M | $— | — |
| Q4 null | $4.0M | 100.0% | $-33.8M | $-28.7M | $— | — |
| FY null | $7.0M | 100.0% | $-139.7M | $-127.2M | $— | — |
| Q3 null | $3.0M | 100.0% | $-34.4M | $-32.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-37.2M | $-34.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.3M | $-31.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-37.4M | $-33.1M | $-0.48 | — |